Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

20% Alcohol With Steroid Local Anesthetic Technique Versus Steroid Local Anesthetic Technique Only in Stellate Ganglion Injection in Idiopathic Palmar Hyperhydrosis

22. August 2026 aktualisiert von: Atef Mohamed mahmoud, Fayoum University Hospital

20% Alcohol With Steroid Local Anesthetic Technique Versus Steroid Local Anesthetic Technique Only in Stellate Ganglion Injection in Idiopathic Palmar Hyperhydrosis: A Controlled Randomised Study.

Palmar hyperhidrosis is a medical condition characterized by excessive sweating specifically from the palms of the hands. This condition can significantly impact an individual's quality of life, leading to social embarrassment, anxiety, and difficulties in daily activities. It is classified as a type of primary hyperhidrosis, which means it occurs without an identifiable underlying medical cause.

The prevalence of palmar hyperhidrosis is estimated to affect about 1% to 3% of the population. Symptoms typically begin in childhood or adolescence, often becoming more pronounced during periods of hormonal changes such as puberty. The condition may run in families, suggesting a genetic predisposition.

The underlying mechanism involves hyperactivity of the sympathetic nervous system, particularly affecting the eccrine sweat glands located in the palms .

Unlike normal sweating, which primarily serves thermoregulation (cooling the body), palmar hyperhidrosis is triggered by emotional stimuli such as stress or anxiety rather than heat. This inappropriate activation leads to excessive sweating that can occur even at rest .

Diagnosis is primarily clinical and based on patient history and visible signs of excessive sweating. Patients often report episodes that are bilateral and symmetrical, with cold and wet palms that may appear pale or blushed. The diagnosis does not typically require extensive testing unless secondary causes are suspected.

Treatment for palmar hyperhidrosis can be challenging due to varying degrees of severity and individual responses to therapies.

Common treatment options include topical treatments as aluminum chloride hexahydrate which is considered one of the most effective topical treatments for palmar hyperhidrosis. It works by blocking sweat pores and reducing gland activity. Application involves using a concentrated solution on dry skin at night until symptoms improve, followed by maintenance therapy.

Another option of treatment is iontophoresis; this technique uses electrical currents to temporarily block sweat gland function. It requires multiple sessions but can be effective for many patients.

Botulinum toxin type A can be injected into affected areas to inhibit neurotransmitter release responsible for activating sweat glands. While effective, this treatment requires repeated injections every few months due to its temporary effects .

Anticholinergic drugs have been used but are often limited by side effects such as dry mouth and constipation at effective dosages .

Regarding surgical options; surgical sympathectomy is considered a last resort for severe cases where other treatments have failed. This procedure involves cutting nerves that trigger sweating but carries risks such as compensatory sweating in other body areas.

Finally, palmar hyperhidrosis is a common yet often underreported condition that can severely affect individuals' lives due to its social implications and discomfort associated with excessive sweating. Treatment options vary widely in effectiveness and side effects, necessitating a tailored approach based on individual needs.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Detaillierte Beschreibung

Study tools:

  1. After approval of study protocol, patients will be enrolled into the study according to inclusion and exclusion criteria.
  2. A total of 50 patients will be categorized into 2 groups:

    • Group A "Stellate Ganglion Block 20% alcohol with steroid local anesthetic technique
    • Group B " Stellate Ganglion Block steroid local anesthetic technique only
  3. Patients will give their consent after having been fully informed about the more frequent side effects of each procedure, such as compensatory sweating and especially those after the block : interscapular pain, transient pneumothorax, and Horner's syndrome.
  4. Objective Sweating Assessment:

    • Patients transferred from dermatology clinic after Diagnosis with primary hyperhidrosis and failed topical treatement.
    • asses severity of sweating by HDSS.
  5. Stellate Ganglion Block 20% alcohol with steroid local anesthetic technique

    • The patient will be placed in the supine position on the operating table.
    • Routine monitoring: pulse oximetet, ABP&ECG
    • IV canula
    • patient will sedate befoer starring the procedure By "midathetic +fentanyl"
    • support the patient with oxygen By nasal canula sterilized drape will be used to ensure safety. The needle tip will be placed in the stellate ganglion under ultrasound guidance "high frequency linear probe" EG LOGIQ L6-12-RS" Alcohol 20% 2ml, lidocaine" 2% 3ml, Dexamethasone amp 8mg 2ml and 3ml normal saline will be used for Stellate Ganglion Block. inject a total of 10 mL of the mixture.

    Follow up Signs of success of the block as drop of eye lid, redness eye and flushing of half side of the face Follow up hotness and dryness of hand after 1 hour of injection . Follow up after 1 week, injection may be repeated If dryness disappear.

  6. Stellate Ganglion Block steroid local anesthetic technique only

    • The patient will be placed in the supine position on the operating table.
    • Routine monitoring: pulse oximetet, ABP&ECG
    • IV canula
    • patient will sedate befoer starring the procedure By "midathetic +fentanyl"
    • support the patient with oxygen By nasal canula
    • sterilized drape will be used to ensure safety.
    • The needle tip will be placed in the stellate ganglion under ultrasound guidance "high frequency linear probe" EG LOGIQ L6-12-RS"
    • xylocaine" lidocaine" 2% 3ml, dexamethasone amp 2ml and 5ml normal saline with total of 10ml will be used for Stellate Ganglion Block.
    • Follow up Signs of success of the block as drop of eye lid, redness eye and flushing of half side of the face
    • Follow up hotness and dryness of hand after 1 hour of injection .
    • Follow up after 1 week, injection may be repeated If dryness disappear.
  7. Follow-Up

    Follow-up will include periodical outpatient visits during which all evaluations will be repeated. Owing to rapid response, forefinger temperature will also be determined 1 hour after treatment.

    Follow up for 6 months

  8. Assessment:

    • Presence/absence of hyperhidrosis: Hyperhidrosis Disease Severity scale " HDSS "will be used, involving asking the patients to describe their sweating status before and after treatment.

A score of 1 or 2 will be classified as mild or moderate hyperhidrosis. A score of 3 or 4 will be classified as severe hyper-hidrosis. A 1-point decrease in the patient's sweating scale means a 50% decrease in sweat production, and a 2-point decrease means an 80% decrease in sweat production, a 3-point decrease means about an 90% decrease in sweat production (Solish et al., 2007).

  • Compensatory hyperhidrosis events:classified as no compensatory hyperhidrosis, Mild (i.e., sometimes sweaty and sometimes not sweaty), Moderate (i.e., constantly aware but not troublesome or troublesome but controlled by clothing), and Severe (i.e., causing embarrassment or regret over having undergone endoscopic thoracic sympathectomy) (Purtuloglu et al., 2013).
  • Other outcomes will include patient satisfaction (satisfied or not satisfied), preoperative, intraoperative, and postoperative evaluation of measured hemodynamic parameters, and other complications (i.e., pneumothorax, hematoma, ptosis, muscle weakness, and muscle spasm).
  • A cost comparison between groups concerning devices, drugs, global time in operating room, medical personnel, and hospital stay will also be carried out.

Study outcomes:

  • Primary outcome: hyperhydrosis severity scale i.e. presence/absence of hyperhidrosis.
  • Secondary outcome parameters:

    • Compensatory hyperhidrosis events,
    • Patient satisfaction (satisfied or not satisfied),
    • Preoperative, intraoperative, and postoperative evaluation of measured hemodynamic parameters.

      . Number of injection needed to overcome hyperhydrosis.

    • Complications (i.e., pneumothorax, hematoma, ptosis, muscle weakness, and muscle spasm).
    • Cost.
    • Time in operating room.
    • Hospital stay.

Ethical Consideration:

Participating patients will sign informed written consent after thorough explanation of the details and purpose of the current study.

Patients have the right to withdraw from the study at any phase without being adversely impacted regarding the medical care they should receive.

The study protocol will be approved by the Ethical Research Committee of Anesthesia Department and Faculty of Medicine, Fayoum University.

Confidentiality of data will be maintained by the following:

  • Substitution of codes for information that identifies the participant (e.g., using numbers instead of names to identify participants).
  • Removal of face sheets that contain identifiers, such as names.
  • Files containing electronic data will be password-protected and encrypted (at least when data were transferred or transported) and closed when computers will be left unattended.
  • Limited access to all data that identifies participants.
  • Paper records will be stored in locked cabinets.
  • Consents will be stored securely in locked cabinets, separately from the research data.
  • Proper disposal of all paper documents that contain identifiers .Statistical analysis and statistical package:

Data will screen, for normality assumption test and homogeneity of variance, normality test of data using Kolmogorov Smirnov test will use, that reflect the data is normally distributed or non-normally distributed after removal outliers that detect by box and whiskers plots. All these findings will allow conducting parametric or non-parametric analysis. The statistical analysis will conduct by using statistical SPSS Package program version 25 for Windows (SPSS, Inc., Chicago, IL). The following statistical procedures will perform for:

  1. Parametric data will express as the mean and standard deviation (SD) for major variables. Independent (unpaired) t-test will use to compare between both groups (misoprostol group vs. lidocaine spray group) for major outcome variables.
  2. Non-parametric data will express as the median and interquartile range (IQR) for major variables. Mann-Whitney U test will use to compare between both groups (misoprostol group vs. lidocaine spray group) for major outcome variables.
  3. Statistical level all statistical analyses for parametric and non-parametric data are significant at level of probability less than an equal 0.05 (P ≤ 0.05).

Studientyp

Interventionell

Einschreibung (Geschätzt)

50

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  1. Age from 18 to 45 years.
  2. Both genders.
  3. Exhibiting primary palmar hyperhidrosis.
  4. All patients with hyperhidrosis and were socially, professionally, and psychologically handicapped.
  5. All patients with failed previous dermatological topical treatment as aluminum chloride hexahydrate

Exclusion Criteria:

  1. An inability of patient to cooperate.
  2. Known allergies to alcohol or local anaesthetic.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Stellate Ganglion Block 20% alcohol with steroid local anesthetic technique
The aim of the study is to compare between 20% alcohol with steroid local anesthetic technique versus steroid local anesthetic technique only in stellate ganglion injection in treatment of idiopathic palmoplantar hyperhidrosis.
Aktiver Komparator: Stellate Ganglion Block steroid local anesthetic technique only
The aim of the study is to compare between 20% alcohol with steroid local anesthetic technique versus steroid local anesthetic technique only in stellate ganglion injection in treatment of idiopathic palmoplantar hyperhidrosis.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
hyperhydrosis severity scale
Zeitfenster: After 1 hour of injection
presence/absence of hyperhidrosis
After 1 hour of injection

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Atef M Sayed, MD, Faculty of medicine, Fayoum university

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. September 2026

Primärer Abschluss (Geschätzt)

1. Oktober 2027

Studienabschluss (Geschätzt)

1. Oktober 2027

Studienanmeldedaten

Zuerst eingereicht

22. August 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. August 2026

Zuerst gepostet (Tatsächlich)

26. August 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

26. August 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. August 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren